Role of MTHFR gene polymorphisms, serum tissue inhibitor of metalloproteinases-1, thymus chemokine-1 and thrombospondin-1 in endometrial cancer

The aim of this study was to evaluate the relationship between the MTHFR gene variants (677 C→T and 1298 A→C), serum tissue metalloproteinases inhibitor (TIMP-1), thrombospondin-1 (TSP-1), thymus chemokine-1 (TCK-1) levels and endometrial cancer. Sixty women were chosen from endometrial cancer patients and fifty-six women without any systemic disease were included as the control group. MTHFR C677T and A1298C MTHFR polymorphisms and their allele frequencies were evaluated with strip assay (Reverse hybridization method). Serum tissue inhibitor of metalloproteinases-1, thymus chemokine-1, and thrombospondin-1 levels were measured with the enzyme-linked immunosorbent assay (ELISA). Genotypic distribution and allelic frequencies of MTHFR C677T polymorphism were not associated with endometrial cancer (P > 0.05). But, genotypic distribution and allelic frequencies of MTHFR A1298C polymorphism were strongly associated with endometrial cancer (P = 0.047 and P = 0.024). On the other hand, tissue inhibitor of metalloproteinases-1, thrombospondin-1, and thymus chemokine-1 levels were strongly associated with endometrial cancer (P = 0.001, P = 0.02, and P = 0.001 respectively). These results indicate that genotypic distribution and allelic frequencies of MTHFR A1298C polymorphism, tissue inhibitor of metalloproteinases-1, thrombospondin-1 and thymus chemokine-1 may be the prognostic markers in endometrial carcinoma.